Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 1 to 10 of 1447 total matches.
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
, connective tissue diseaseassociated,
or after shunt correction; WHO Group 1
The Medical Letter ® Vol. 66 ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
rheumatica than in those with rheumatoid arthritis.
The Medical Letter ® Vol. 66 (1702) May 13, 2024
78
1 ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
In Brief: Casgevy for Beta Thalassemia
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
dose is $2.2 million for
Casgevy compared to $2.8 million for Zynteglo.5
The Medical Letter ® Vol ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based
gene therapy recently approved for treatment
of sickle cell disease1, has now been approved by
the FDA for treatment of patients ≥12 years old with
transfusion-dependent beta thalassemia. Casgevy is
the first gene therapy that uses CRISPR/Cas9 gene-editing
technology to be approved in the US for any
disorder. Betibeglogene autotemcel (Zynteglo), an
autologous lentiviral vector cell-based gene therapy,
was approved in the US in 2022 for treatment of
transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79 doi:10.58347/tml.2024.1702d | Show Introduction Hide Introduction
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
administration of a COVID-19 vaccine, or as a
substitute for vaccination.5
The Medical Letter ® Vol. 66 (1702 ...
The FDA has issued an Emergency Use Authorization
(EUA) for the long-acting investigational IV
monoclonal antibody pemivibart (Pemgarda –
Invivyd) for pre-exposure prophylaxis of COVID-19
in persons ≥12 years old (weight ≥40 kg) who have
moderate to severe immune compromise and
are unlikely to respond adequately to COVID-19
vaccination (see Table 1). Pemgarda is the only drug
that is currently authorized in the US for pre-exposure
prophylaxis of COVID-19. Tixagevimab/cilgavimab
(Evusheld) was previously available under an EUA for
this indication, but it lacks activity against...
Med Lett Drugs Ther. 2024 May 13;66(1702):79-80 doi:10.58347/tml.2024.1702e | Show Introduction Hide Introduction
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
of MASH resolution with no worsening of fibrosis
The Medical Letter ® Vol. 66 (1701) April 29, 2024
66 ...
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone
receptor-beta agonist, has received accelerated
approval from the FDA for treatment of noncirrhotic
nonalcoholic steatohepatitis (NASH) with moderate
to advanced fibrosis in adults. NASH has recently
been renamed metabolic dysfunction-associated
steatohepatitis (MASH). Resmetirom is the first drug
to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-6 doi:10.58347/tml.2024.1701a | Show Introduction Hide Introduction
A New Indication for Semaglutide (Wegovy)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
, or upper arm once weekly.
The Medical Letter ® Vol. 66 (1701) April 29, 2024
67
1. Semaglutide (Wegovy ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has been
approved by the FDA to reduce the risk of major
adverse cardiovascular events (MACE) in adults with
established cardiovascular disease (CVD) and either
obesity or overweight. Semaglutide is the first drug
to be approved for cardiovascular risk reduction in
this population. It is also approved in a lower-dose
injectable formulation as Ozempic and in an oral
formulation as Rybelsus (see Table 1).
Med Lett Drugs Ther. 2024 Apr 29;66(1701):66-7 doi:10.58347/tml.2024.1701b | Show Introduction Hide Introduction
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
score.
The Medical Letter ® Vol. 66 (1701) April 29, 2024
69
Table 2. Some IV Nonopioid Analgesics ...
The FDA has approved Combogesic IV (Hikma), an IV
solution containing acetaminophen and ibuprofen, to
treat mild to moderate pain (alone) or moderate to
severe pain (in combination with an opioid) in adults
when IV analgesia is considered clinically necessary.
Single-drug IV solutions containing ibuprofen
(Caldolor) and acetaminophen have been available in
the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9 doi:10.58347/tml.2024.1701c | Show Introduction Hide Introduction
iDose TR — A Travoprost Implant for Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
cost (WAC) of one iDose
TR implant is $13,950.4
The Medical Letter ® Vol. 66 (1701) April 29, 2024 ...
The FDA has approved iDose TR (Glaukos), an
intracameral implant containing the prostaglandin
analog (PGA) travoprost, for reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension. Travoprost is also available
as a topical ophthalmic solution (Travatan Z, and
generics) for the same indication. iDose TR is the
second ocular implant to become available in the US
for this indication; Durysta, an intracameral implant
containing the prostaglandin analog bimatoprost,
was the first.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):70-1 doi:10.58347/tml.2024.1701d | Show Introduction Hide Introduction
Antibiotic Prophylaxis for Dental Procedures
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
for patients
with orthopedic implants.5,6
The Medical Letter ® Vol. 66 (1701) April 29, 2024
Letter
Table ...
Since 2007, antimicrobial prophylaxis for dental
procedures has been recommended to prevent
viridans group streptococcal infective endocarditis
only for patients at highest risk of an adverse
outcome. Limiting use to such patients does not
appear to have led to an increased incidence of
infective endocarditis or increased mortality due to
infective endocarditis.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):71-2 doi:10.58347/tml.2024.1701e | Show Introduction Hide Introduction
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
Letter ® Vol. 66 (1700) April 15, 2024
58
Table 3. Some Topical Products for Seborrheic Dermatitis1 ...
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 doi:10.58347/tml.2024.1700a | Show Introduction Hide Introduction